Apheresis as Therapy
Aferetica is an Innovative Small and Medium-sized Enterprise (SME), founded by Managers with tens of years of experience in Dialysis, Intensive Care, Cardiology and Medical Devices.
The company proposes itself as a catalyst for the creation of a Network of Clinicians, Academics, Researchers and Institutions, to create and validate New Apheretic Therapies, even for unexplored clinical areas.
An integrated and innovative vision of apheretic therapies is the challenge to face for a real evolution of the cure.
Last updates
Save the Date WPT 2025
We’re very glad to announce the 4th Workshop Purification Therapies ‘From Research to Clinics: The End of the Beginning'
Towards Purification Therapies Workshop 2022
At the end of the year, Purification Therapies Journey 2021 came to an end.
The integrated PerLife(R) system with “PerSorb ECOS-300CY™” sorbent obtains CE certification and is ready to enter in the clinical practice.
CytoSorbents (USA) and Aferetica announce the European Union's approval for clinical use of the integrated PerLife® system and the "PerSorb ECOS-300CY ™" sorbent
Events
ACHBT Congress
The 8th appointment of the PTJ 2024 is the ACHBT Congress - Association de Chirurgie Hépato-Bilio-Pancréatique et Transplantation, from March 28th to 29th at the Metropole Hotel, Lyon (France).
CKRT in the newborn and critical child
Our 7th appointment of the Purification Therapies Journey 2024, the ECM Course ‘Continuous kidney replacement therapy (CKRT) in the newborn and critical child’, will be held from March 27th to 28th at the Bambino Gesù Pediatric Hospital (Rome).
43rd ISICEM Congress
6th event of the Purification Therapies Journey 2024 is the 43rd ISICEM Congress - International Symposium on Intensive Care & Emergency Medicine